Momenta Prices $40M Stock Offering

Ryan McBride9/23/09

Momenta Pharmaceuticals (NASDAQ:MNTA), a Cambridge, MA-based developer of generic and original biotech drugs, reports this morning that it has priced an offering of 4 million shares of its common stock at $10.75 per share. The offering, which is due to close on September 28, is expected to net the company $40.6 million. The stock offering comes as the company continues its years-long wait for the FDA to okay its application to begin sales of its generic version of blood thinner enoxaparin, which French drug giant Sanofi-Aventis markets as Lovenox.